Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: ValuEngine, Inc.
$25.00
Provider: Reuters Investment Profile
$20.00
Provider: MarketLine (a Datamonitor Company)
$175.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Astellas Pharma Inc and AVEO Oncology Announce Submission of New Drug Application for Tivozanib for the Treatment of Advanced Renal Cell Carcinoma


Sunday, 30 Sep 2012 07:00pm EDT 

Astellas Pharma Inc and AVEO Oncology announced that AVEO has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for tivozanib in patients with advanced renal cell carcinoma (RCC). Tivozanib is designed to target the vascular endothelial growth factor (VEGF) pathway, a clinically validated target in RCC and other solid tumors. 

Company Quote

1404.0
22.0 +1.59%
22 Jul 2014